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Abstract
Background: NT-proBNP has prognostic implications in heart failure. In acute coronary syndromes (ACS) setting, the
prognostic significance of NT-proBNP is being sought. We studied short-term prognostic impact of admission NT-proBNP
in patients admitted for ACS and in association with GRACE risk score (GRS). Methods and Results: We studied 1035
patients admitted with ACS. Patients were divided in quartiles according to NT-proBNP levels on admission: Q1 B180 pg/
ml; Q2 180691 pg/ml; Q3 6962664 pg/ml; Q4 269835 000 pg/ml. Groups were compared in terms of short-term all-
cause mortality. Patients with higher NT-proBNP had worst GRS on admission. They also received less aggressive
treatment. In-hospital mortality was 0.8%, 3.0%, 5.8% and 12.8% (PB0.001) and 30-day mortality 1.6%, 4.6%, 6.5% and
16.7% (PB0.001) respectively. In multivariate logistic regression analysis, NT-proBNP is an independent predictor of in-
hospital (OR 2.35; 95% CI: 1.124.93, P0.022) and 30-day mortality (OR 2.20; 95% CI: 1.174.12, P0.014).
However, NT-proBNP does not add any incremental benefit to GRS for prediction of outcome by ROC curve analysis.
Conclusions: NT-proBNP is an independent predictor of in-hospital and 30-day mortality after ACS, independently of left
ventricular function, but does not increase the prognostic accuracy of GRS.
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Introduction
During the last decade, B-type natriuretic peptide
(BNP) has been recognized as a useful marker for
the detection of acute and chronic left ventricular
dysfunction (1,2). Acute regional diastolic and/or
systolic left ventricular dysfunction is a hallmark of
sudden and prolonged myocardial ischaemia (3). In
fact, natriuretic peptides have been found to be
elevated in the setting of acute coronary syndromes
(ACS). In ST-segment elevation, peak values are
observed 16 hours after admission with over one-half
of the patients developing a second peak by the fifth
day (4). BNP is produced by myocardial cells when
submitted to wall stress or overload, especially if
systolic dysfunction is present (1,4).
N-terminal-pro-BNP (NT-proBNP) is the amino
terminal product after cleavage of the precursor
peptide of BNP (4). This molecule has a longer
half-life that may allow for greater accumulation of
NT-proBNP and a greater sensitivity in detecting
more subtle structural and functional changes (5).
Risk prediction based on clinical, ECG, and
biochemical (cardiac troponin) markers, is relatively
inaccurate (6). The development of risk scores, such
as GRACE risk score, associating several variables,
improved the predictive capacity, but requires sev-
eral measurements on admission (7).
In the present study, we evaluated the short-term
prognostic value of an early measurement of NT-
proBNP in a wide cohort of patients encompassing
the whole spectrum of ACS. We also studied if
NT-proBNP has any incremental value when asso-
ciated with GRACE risk score for the prediction of
outcome.
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Materials and methods
The present study is a retrospective analysis of an
internal registry of ACS (based on GRACE registry)
that included consecutive patients from January
2005 to July 2007, admitted at our Intensive Care
Unit for ACS. Inclusion criteria were*clinical
history consistent with new onset or a worsening
pattern of characteristic ischemic chest pain in the
previous 24 h, occurring at rest or with minimal
exertion (lasting longer that 10 min) and at least one
of the following: ECG changes compatible with
ischemia (ST-segment depression, elevation or T
wave inversion) or elevated cardiac enzymes or
biomarkers (Troponin T) above the upper limit of
normal. Baseline demographics, clinical history, and
objective assessment of clinical signs were obtained.
Follow-up was performed in all surviving patients by
telephone interview 30 days after admission. All
cause mortality was evaluated at 30 days of the
follow-up period.
Plasma NT-proBNP was incorporated into the
diagnostic protocol and obtained on admission and
serial measurements were made until discharge.
Venous blood samples were obtained by direct
venous puncture. Blood samples were collected in
tubes without anticoagulant, centrifuged, and serum
was analysed within 3 hours. Serum NT-proBNP
was determined, with an electrochemiluminescence
immunoassay (ECLIA) on an Elecsys 2010 analyser
(Roche Diagnostics). The analytical range of this
assay extended from 5 to 35 000 pg/ml. At our
laboratory, total precision has a coefficient of
variation of 2.9% and 1.9% using Roche Precicon-
trol II, 1 and 2 respectively. Serum creatinine was
analysed by a Jaffe timed rate method, and estimat-
ed creatinine clearance was calculated with the
Cockcroft-Gault equation (8).
The study complies with the principles outlined
in the Declaration of Helsinki and patients gave
informed consent for inclusion in the registry and for
follow-up contact.
Statistical analysis
Continuous data were presented as mean9SD
(median and 2575th percentile for skewed vari-
ables) and were compared with ANOVA test or
KruskalWallis test. Categorical variables were pre-
sented as frequencies and percentages and were
compared using Chi-square test.
Patients were divided in quartiles according to
NT-proBNP levels on admission: Q1 (B180 pg/ml),
Q2 (180691 pg/ml), Q3 (6962664 pg/ml) and Q4
(2698 pg/ml). Blood glucose, estimated creatinine
clearance (eCrCl), admission and peak NT-proBNP
levels and peak creatinine kinase were much skewed.
A 10-base logarithmic transformation was done and
log-transformed variables were used throughout.
Pearson’s correlation coefficient and linear re-
gression analysis was computed to examine the
association between NT-proBNP and other vari-
ables. Receiver operating characteristics (ROC)
curves were generated and the area under the curve
(AUC) (and its 95% confidence intervals) calculated
to determine the best discriminating level of NT-
proBNP for predicting in-hospital and 30-day mor-
tality. Optimal discrimination limits were identified
at the cut-point that maximizes sensitivity and
specificity. ROC curves were constructed for NT-
proBNP, GRACE risk score and a combination of
both (as continuous variables) for the prediction of
all-cause mortality.
Univariate analysis was performed to evaluate the
significance of all variables for prediction of out-
come. All variables with a P-value B0.10 were then
entered into a multivariable logistic regression ana-
lysis. We also included variables that could influence
NT-proBNP levels, identified by linear regression
analysis.
To compare overall diagnostic performance,
comparing the AUC of two ROC curves (admission
NT-proBNP and GRACE risk score), we used the
bivariate chi-square test with ROCKIT 1.1B2 soft-
ware b version (Chicago, Illinois). All the other data
analysis was performed using SPSS version 10.0
(SPSS Inc. Chicago, Illinois). A P-value B0.05 was
considered statistically significant.
Results
Study population consisted of 1035 patients with
NT-proBNP measurements (out of a total of 1113
patients included in our registry), 72% males, aged
63913 years. The median time from the beginning
of symptoms to first blood collection for NT-
proBNP assessment was 8.5 h (417.5) in the overall
population, 5.5 h (313) in the group with ST-
segment elevation and 14 h (7.523.5) in the group
with ACS with non-ST-segment elevation. Patients’
characteristics are shown in Table I. Age, hyperten-
sion, previous myocardial infarction (MI), previous
percutaneous coronary intervention (PCI) and
blood glucose on admission increased along with
the quartiles. Male gender, smoking, total choles-
terol, LDL-cholesterol, triglycerides and eCrCl de-
creased. ST-segment elevation acute MI and a lower
Killip class was more frequent in lower quartiles.
Patients in the highest quartiles received less clopi-
dogrel, beta-blockers, statins and PCI (Table II).
The unadjusted mortality rate (in-hospital and 30-
day mortality) increased directly across quartiles of
NT-proBNP (PB0.001) (Figure 1).
In bivariate analysis, higher baseline levels of NT-
proBNP were directly associated (with fair correla-
tion) with age (r0.46, pB0.001), history of
hypertension (r0.24, PB0.001), diabetes (r
0.18, PB0.001) and smoking (r0.29, PB0.001).
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An inverse association was seen with eCrCl (r
0.51, PB0.001) and weight (r0.20, PB
0.001). No correlation was found with BMI. There
was also a significant correlation between GRACE
risk score and NT-proBNP (R0.51, PB0.001).
ROC curve analysis showed that admission NT-
proBNP measurements are predictive of in-hospital
and 30-day mortality (Figure 2). The AUC for in-
hospital mortality was 0.74 (95% CI: 0.670.81; PB
0.001) and for 30-day mortality, 0.73 (95% CI:
0.670.79; PB0.001). The results were similar for
peak NT-proBNP: in-hospital mortality AUC 0.82
(95% CI: 0.760.89; PB0.001); 30-day mortality,
AUC 0.80 (95% CI: 0.740.86; PB0.001). The
curves were used to determine cut points to evaluate
the likelihood of death for admission NT-proBNP.
Decision limits yielding 57% sensitivity are 2884 pg/
ml (79% specificity) for in-hospital death and
2818 pg/ml (78% specificity) for 30-day mortality.
The same analysis was done for GRACE risk score
in the present population of patients, with more
significant results (Table III). The AUC of NT-
proBNP for in-hospital mortality is significantly
lower when compared with GRACE risk score
AUC (Chi-square statistic12.91, PB0.001) as
well as for 30-day mortality (Chi-square statistic
11.18, P0.0037). The combined index of GRACE
risk score and NT-proBNP was studied by ROC
curve analysis and the combination did not yield
incremental value over GRACE risk score alone
(Table III).
Univariate analysis showed that admission NT-
proBNP levels (for the cut-offs obtained before) are
predictors of in-hospital death (OR 4.76; 95% CI:
2.778.19; PB0.001) and 30-day death (OR 4.68;
95% CI: 2.907.55; PB0.001). Patients with high
GRACE risk score*high NT-proBNP (GRACE risk
score patients divided in tertiles and admission NT-
proBNP divided by the cut-off values identified by
ROC curve analysis) were more likely to have









Age (years) 56911 62913 66912 73911 B0.001
Male gender 223 (86) 199 (76) 166 (64) 124 (48) B0.001
BMI (kg/m2) 2793 2798 2795 2794 NS
Hypertensiona n (%) 118 (46) 168 (65) 187 (72) 195 (76) B0.001
Hyperlipidemiab n (%) 145 (56) 116 (45) 125 (48) 119 (46) 0.04
Diabetes n (%) 40 (15) 54 (21) 75 (29) 90 (35) B0.001
Smoking n (%) 143 (55) 100 (38) 82 (31) 43 (17) B0.001
Previous MI n (%) 27 (10) 36 (14) 47 (18) 52 (20) 0.01
Prev. revascularization n (%) 30 (11) 38 (14) 43 (16) 38 (15) NS
ST-segment elevation n (%) 180 (70) 162 (62) 146 (56) 124 (48) B0.001
Killip class1 n (%) 13 (5) 19 (7) 32 (12) 74 (29) B0.001
LVEFB40% n (%) 5 (2) 11 (4) 28 (11) 49 (19) B0.001
Blood glucose (mg/dl) 129 (112167) 132 (107170) 141 (112180) 151 (121204) B0.001
eCrCl (ml/min) 95 (78115) 86 (66108) 74 (5795) 52 (3773) B0.001
Total cholesterol (mg/dl) 202947 194946 188953 171941 B0.001
HDL-cholesterol (mg/dl) 38912 39912 40916 40912 NS
LDL-cholesterol (mg/dl) 135944 130937 122943 110935 B0.001
Peak CK (UI/ml) 1132 (3492952) 804 (2302262) 906 (2362414) 755 (2422235) NS
Peak Troponin T (ng/ml) 2.74 (0.397.13) 2.04 (0.46.29) 2.46 (0.6 5.75) 2.93 (0.977.63) 0.059
Ad. NT-proBNP (pg/ml) 65 (30111) 361 (242518) 1431 (10071995) 6073 (370712004) B0.001
P. NT-proBNP (pg/ml) 458 (1151407) 2129 (3831834) 3420 (12893779) 12040 (419916128) B0.001
GRACE risk score 124929 137933 148932 174935 B0.001
aHistory of hypertension according to the patient.
bHistory of hyperlipidemia that required medical therapy according to the patient.
BMI, body mass index; MI, myocardial infarction; LVEF, left ventricular ejection fraction; eCrCl, estimated creatinine clearance; CK,
creatinine kinase; Ad., admission; P., peak.









Aspirin n (%) 253 (98) 256 98) 250 (96) 247 (96) NS
Clopidogrel n (%) 241 (93) 242 (93) 235 (90) 216 (84) 0.001
ACEI n (%) 210 (81) 216 (83) 229 (88) 226 (88) 0.07
Beta-blocker n (%) 228 (88) 212 (81) 210 (81) 187 (73) B0.001
Statin n (%) 248 (96) 243 (93) 234 (90) 227 (88) 0.005
PCI n (%) 174 (67) 130 (50) 114 (44) 81 (32) B0.001
IIb/IIIa antagonists n (%) 143 (55) 107 (41) 88 (34) 64 (25) B0.001
ACEI, angiotension converting enzyme inhibitor; PCI, percutaneous coronary intervention.
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in-hospital (RR 1.56; 95% CI: 0.932.61; P0.09)
and particularly 30-day death (RR 1.98; 95% CI:
1.223.22; P0.007) when compared to patients
with high GRACE risk score*low admission NT-
proBNP.
In a multivariate logistic regression model ad-
justed for other predictors of death (identified by
univariate analysis) or related to an elevated
NT-proBNP (including age, weight, hypertension,
diabetes, smoking, stage 2 or worse chronic kidney
disease*eCrCl B90 ml/min/m2, Killip class ]2,
ST elevation myocardial infarction, ACE inhibitor,
beta-blocker, statins, LVEF 540%, blood glucose
on admission, peak CK and admission NT-
proBNP), NT-proBNP levels on admission were an
independent predictor of in-hospital death (OR
2.02; 95% CI: 1.213.39; P0.008) and 30-day
mortality (OR 1.86; 95% CI: 1.202.88; P0.005)
(Tables IV and V).
Discussion
The roles of BNP and NT-proBNP are well estab-
lished for heart failure (1,2). However, their utility in
ACS is still evolving. BNP has a well-defined
mechanism of elimination: degradation by circulat-
ing endopeptidases, clearance by cellular binding
receptors and to a lesser degree by renal excretion
(9). Recent reports showed that NT-proBNP and
BNP are equally dependent on renal function for
clearance, suggesting also a saturable clearance
mechanism for NT-proBNP degradation indepen-
dent of glomerular filtration, yet unknown (10). NT-
proBNP has a longer half-life (70120 min) that may
allow for greater accumulation and potentially
greater sensitivity in detecting more subtle structural
and functional changes (9,10). In our population,
NT-proBNP was directly correlated with age, hy-
pertension, diabetes and smoking and inversely


































Figure 2. ROC curves for admission NT-proBNP, GRACE risk
score and a combination index to predict in-hospital and 30-day
mortality.
Table III. ROC curves analysis for admission NT-proBNP and
GRACE risk score for the prediction of death and a combination
score: AUC (95% CI), P-value.

















aCombination of increasing GRACE risk score and increasing
admission NTproBNP.
Table IV. Multivariate analysis for inhospital mortality (inde-
pendent predictors).
OR 95% CI P-value
Admission NT-proBNP 2.02 1.213.39 0.008
Age 1.05 1.011.09 0.023
ST-elevation MI 2.74 1.146.54 0.024
Beta-blocker 0.19 0.090.39 B0.001
LVEF B40% 4.54 2.079.95 B0.001
Blood glucose 24.47 3.57167.69 0.001
MI, myocardial infarction; LVEF, left ventricular ejection fraction.
Variables included in the model: age, weight, hypertension,
smoking, diabetes, eCrCl B90 ml/min, Killip class ]2, ST
elevation myocardial infarction, ACE inhibitor, beta-blocker,
statins, LVEF540%, blood glucose on admission, peak CK and
admission NT-proBNP.
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correlated with eCrCl and weight, confirming pre-
vious studies, particularly on eCrCl and obesity
(11,12).
Acute regional diastolic and/or systolic left ven-
tricular dysfunction is a hallmark of sudden and
prolonged myocardial ischemia, and is one of the first
steps in the ischemic cascade that leads to cell necrosis
(3). The prognostic accuracy of early measurement of
NT-proBNP was greater than that of early measure-
ments of troponin T in the study by Galvani,
suggesting that NT-proBNP might be considered an
early ischemic marker (13). Such early increases may
reflect the amount of the ischaemic insult to the
myocardium, rather that the actual extent of myo-
cardial necrosis. Myocardial cell death (and the
release of its necrosis markers) is a final event (3).
BNP was found to be very useful in the emergency
department for the diagnosis of acute MI in patients
with chest pain, particularly when standard cardiac
markers are non-diagnostic (14). In fact, BNP has
been found to increase in the setting of MI with peak
levels occurring 14 to 40 h after the ischemic event
(4). The degree of natriuretic peptide elevation is
related to the size of the ischaemic injury (4).
Patients in the highest quartiles were treated less
aggressively. The explanation for that is related to
the fact that the majority of patients in these groups
had non ST-segment elevation ACS and underwent
PCI less often (as usual in non ST-segment elevation
compared with ST-segment elevation ACS). This
fact in association with the high in-hospital mortality
rate in these groups (in most cases very soon after
admission, not allowing for appropriate treatment to
be provided) can explain the lowest rate of PCI,
clopidogrel, beta-blockers and statins.
Analysis of the sensitivity and specificity of using
NT-proBNP to predict death was accomplished by
evaluating ROC curves. Admission NT-proBNP was
found to be useful for assessing prognosis as well as
peak NT-proBNP; however, peak values are a later
marker. We demonstrated that as a single prognostic
marker, admission NT-proBNP has a good overall
diagnostic performance for the prediction of death in
short-term follow-up. When we evaluated the overall
diagnostic performance by comparing the areas
under the ROC curves for NT-proBNP and GRACE
risk score (a score that includes several prognostic
variables), the second one had a better overall
performance.
Previous studies showed that BNP and NT-
proBNP provided additional prognostic information
beyond that of TIMI risk score, both in ST-segment
and non-ST-segment elevation acute myocardial
infarction (1518). In our study, combining GRACE
risk score to admission NT-proBNP had no incre-
mental value over GRACE risk score alone for
predicting outcome. TIMI risk score has been
derived from a database of clinical trial. It is possible
that it would have excluded high-risk patients and
may not be fully representative of broad spectrum
patients encountered in clinical practice. GRACE
risk score is a mortality model that span the entire
spectrum of ACS, based in a relatively unselected
patient-population, representing those seen in gen-
eral practice and incorporates new variables that add
considerable predictive information such as renal
dysfunction (one of the most important variables to
predict prognosis in ACS) as well as Killip class.
These variables also correlate with NT-proBNP.
This might explain the fact that combining GRACE
risk score with NT-proBNP did not improve prog-
nostic accuracy. Multivariate analysis confirmed that
admission NT-proBNP can predict in-hospital and
30-day mortality independently of other variables
that can predict death and adjusted for the variables
that influence NT-proBNP levels.
Our results (with a larger patient population) are
consistent with those of Bazzino et al., who showed
that baseline NT-proBNP is an important prognostic
variable in non-ST-elevation ACS and Grabowski
et al, in patients with ST-elevation MI treated with
primary angioplasty (this last study with BNP)
(15,16). The results were also consistent with those
of Galvani et al that compared the whole spectrum
of ACS as our study (13). In fact, higher BNP
concentrations are associated with tighter culprit
lesions, diameter stenosis, left descending artery or
proximal culprit lesion location, slow flow in culprit
artery and no-reflow phenomenon after PCI
(19,20). All of these findings support the hypothesis
that ischemia leads to altered myocardial stretch and
causes active secretion of BNP (21). In fact, Goetze
demonstrated that myocardial ischemia in the
absence of left ventricular dysfunction augments
cardiac BNP gene expression and increases plasma
NT-proBNP concentrations. Quantitative analysis of
BNP mRNA in ventricular biopsies revealed close
association of plasma NT-proBNP to BNP mRNA
levels (22).
Limitations
One limitation of this study is the relatively hetero-
geneous population, since we included the entire
Table V. Multivariate analysis for 30day mortality (independent
predictors).
OR 95% CI P-value
Admission NT-proBNP 1.86 1.202.88 0.005
Beta-blocker 0.25 0.140.46 B0.001
Statin 0.44 0.210.96 0.038
LVEFB40% 3.59 1.787.23 B0.001
Blood glucose 23.67 4.43126.53 B0.001
LVEF, left ventricular ejection fraction.
Variables included in the model: age, weight, hypertension,
smoking, diabetes, eCrCl B90 ml/min, Killip class ]2, ST
elevation myocardial infarction, ACE inhibitor, beta-blocker,
statins, LVEF540%, blood glucose on admission, peak CK and
admission NT-proBNP.
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spectrum of ACS. However, a correction was made
by the inclusion of ST-segment elevation MI in the
multivariate model. The results are also consistent
with Galvani results with the same type of popula-
tion; however, our results were obtained from a
registry that represents a real life population and not
from a trial as in Galvani paper.
Another limitation is that we did not analyse the
influence of time frames in NT-proBNP levels. The
time between the beginning of the acute event and
admission was not specifically analysed. However, all
patients were admitted in the first 24 h of ACS
evolution. Serial measurements of NT-proBNP in
patients with ACS might by used more rapidly to
identify patients suitable for early discharge or more
intensive therapy. An early (at 48 h) and significant
decline (48 h: 24%; 72 h: 49%) compared to
admission, indicates clinical stabilization and a
better 30-day prognosis (23). This aspect was not
analysed due to the fact that our registry only
collected admission and peak NT-proBNP, although
it was not possible to draw any conclusions about the
dynamic evolution of NT-proBNP levels and impact
on prognosis.
A longer follow-up could also show a more
significant impact on prognosis.
Conclusions
In the present study, we demonstrated that early
measurements of NT-proBNP provide important
and independent information for risk stratification
(in-hospital and 30-day mortality) across the entire
spectrum of ACS. This impact is independent of
degree of myocardial damage, left ventricular func-
tion and other clinical risk factors. However, admis-
sion NT-proBNP does not increase the prognostic
accuracy of GRACE risk score. We also confirmed
the relation between NT-proBNP and age, renal
function, body weight, hypertension, smoking and
diabetes.
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